The cost-effectiveness of heart failure (HF) disease management depends on avoiding future high costs. Prospectively identifying HF patients who are likely to incur high costs would be beneficial. METHODS: We used a 100% sample of 1,363,977 Medicare beneficiaries hospitalized with a primary diagnosis of HF (ICD-9-CM codes 428.x, 402.x1, 404.x1, 404.x3) between 2001 and 2004. The earliest HF hospitalization for each beneficiary was considered the index. We summed Medicare payments for rehospitalizations in the year following the index hospitalization, adjusted costs to 2001 dollars, and created a binary variable, with patients in the 4th quartile (>$16,500) defined as "high cost." Comorbidities and risks were obtained from the index claim and from inpatient claims in the prior year. Logistic regression was used to predict high cost status in a 75% random derivation sample; the model was validated in the remaining 25%. We evaluated the calibration and discrimination of the model in both samples and refit the model on the entire sample. RESULTS: Average Medicare payments in the year following index hospitalization were $38,300 (SD $29,146) among high cost patients and $4272 (SD $4857) among patients in the lower 3 quartiles. Inpatient cost in the prior year was the strongest predictor of inpatient cost in the subsequent year (OR 2.31, 95% CI: 2.27-2.35 for prior year inpatient costs >$16,500 vs. no inpatient costs in the prior year.) In both the derivation and validation cohorts, 11% of patients in the lowest decile and 45% of patients in the highest decile were high cost. The model was well-calibrated. The c-statistic was 0.65 for both the derivation and validation cohorts. CONCLUSION: There is limited ability to predict high cost HF patients using claims data alone. Future studies should assess the value of incorporating clinical variables.
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PCV95 IMPACT OF ADOPTION OF NEW ANTIHYPERTENSIVE DRUGS ON THE HEALTH CARE UTILIZATION IN HYPERTENSIVE PATIENTS
Ganguli A, Hong SH, Wingate L University of Tennessee, Memphis, TN, USA OBJECTIVE: This study aims to analyze the hypothesis that utilization of newer medications is associated with decreased health care utilization and increased quality of life in patients with hypertension. METHODS: This is a retrospective follow up study of patients identified as hypertensive (ICD-9-CM codes 401-405) and prescribed at least one antihypertensive medication during round one of 1999 MEPS database. Antihypertensive drugs approved by FDA during the years 1996, 1997 and 1998 were defined as 'new antihypertensive drugs'. New drug adopters (NDA) were those hypertensive patients who were prescribed atleast one new antihypertensive medication. The total health care expenditure and the non-prescription health care expenditure were taken as markers for health care utilization and the number of ER visits was a marker for quality of life of a patient. RESULTS: Fourteen new antihypertensive drugs were approved by FDA during the year 1996 (3), 1997 (7) and 1998 (4). A total of 1149 (un-weighed) patients were identified as the study population of which 63 (5.88%) patients were identified as NDA's. Females comprised 66.67% (42) in NDA's and 49.82% (534) in non-NDA's. The New drug adopters were found to spend $637 & $675 more on total health care expenditure and on nonprescriptions expenses respectively as compared to non-NDA's. Also NDA's had 0.124 more ER visits as compared to non-NDA's. These results were statistically insignificant at 0.05 level when adjusted for age, gender, income, race, ethnicity, number of co-morbid conditions and insurance status. CONCLUSION: No relation was found between the total health care utilization and adoption of newer antihypertensive medications on aggregate level. This signifies the need to scrutinize the pharmacoeconomic evaluation of each new drug before acceptance by physicians and pharmacy managers. In this study, we use data from a large clinical trial of exercise therapy in patients with heart failure to evaluate whether there is evidence of a learning curve with regard to time spent on non-exercise activities across 36 supervised exercise training sessions across 12 weeks. METHODS: As part of the economic evaluation planned alongside the NIH-sponsored HF-ACTION trial, a Provider and Patient Time Assessment Survey was administered across 9 study sites representing a subset of 56 patients. The survey was designed to assess provider time with and without the patient, pre-and post-exercise, to account for a variety of related tasks (e.g. pulling charts, patient education, scheduling, etc.). Linear growth models were used to model the trajectory change of time spent on 'non-exercise' activities across 36 visits. RESULTS: Data were available for 39 (69.6%) patients who completed all 36 exercise sessions, 7 (12.5%) patients who were still enrolled in ongoing exercise training, and 10 (17.9%) patients who discontinued exercise training. The average nonexercise time associated with supervised training was 30.3 (SD = 19.8) minutes, comprised of 20.6 minutes spent with patients and 9.5 minutes without patients. After adjusting for whether warm-up/cool-down activities were included, the total time spent on non-exercise activities decreased significantly (parameter estimate: -1.04 minutes/week; p = 0.007), with approximately equal reductions in time with patients (-0.57 minutes/week; p = 0.038), and without patients (-0.65 minutes/ week; p = 0.058) over 12 weeks. CONCLUSION: Our analysis suggests that providers and patients experienced efficiency gains in regard to time spent on activities associated with supervised exercise training. These results demonstrate the potential importance of comprehensive time assessment when evaluating disease management programs. The goal of the study was to test the effects of step therapy on pharmaceutical and medical utilization and costs. This study examined the effect of step therapy for antidepressant and antihypertensive medications. METHODS: The data was extracted from the MarketScan database, representing the health care experience of enrollees in employer-sponsored, commercial health plans. The sample consisted of employees and dependents of 4 employers (2-step therapy and 2 controls) who were continuously enrolled in the MarketScan database from 2003 through the third quarter of 2006 and who used antidepressants (N = 15,552 step therapy; N = 45,244 control) or antihypertensives (N = 11,851 step therapy; N = 30,822 control) at least once during the study period. An analytic file was created using a panel data framework, yielding 15 observations or quarters of data per patient. Chi-square and Student's t-tests were computed to compare demographic and clinical characteristics as well as outcome variables between the step therapy and comparison groups after step therapy had been implemented for plans with step therapy. Multivariate generalized estimating equation (GEE) models were used to estimate the effects of step therapy on spending and utilization while controlling for important covariates and adjusting for clustering by patient. RESULTS:
PCV96 THE EFFECT OF MEASUREMENT ERROR FROM POINT-OF-CARE INR DEVICES ON WARFARIN DOSING DECISIONS
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PCV98 THE EFFECTS OF STEP THERAPY: LOOKING BEYOND IMPACTS ON PRESCRIBING RATES AND COSTS
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Step therapy had the intended effect of increasing generic prescribing and lowering brand prescribing.
Overall, medication costs were reduced in the step therapy plans in the initial period following implementation. However, inpatient, outpatient, and emergency room utilization and costs were higher in the step therapy plans after step therapy was implemented relative to the comparison groups. Medication discontinuation rates for the targeted drugs increased in step therapy plans. CONCLUSION: Implementation of step therapy produces intended and unintended results. The intended results of reducing drug costs are found to co-occur with unintended results that may adversely affect patients as evidenced by higher ER and inpatient utilization. (ICERs) were calculated using a model to be published in Value in Health. However, for this analysis, we used efficacy estimates from a meta-analysis that compared several statins across dose ranges. Furthermore, we considered two scenarios. In scenario 1, doses are doubled after 12 weeks of treatment if the LDL level is over 115 mg/dL; in scenario 2, the dose is fixed. For the analysis of prescription patterns and costs per dose, we used official data. RESULTS: Results show that, in both scenarios, Pravastatin 10 mg and 20 mg and Atorvastatin 10 mg are dominated. Taking Simvastatin 10 mg as reference, the ICER of Simvastatin 20 mg in scenario 1 is €203,780 and the ICER of Rosuvastatin 10 mg is €108,293, while the ICER of Rosuvastatin 10 mg compared to Simvastatin 20 mg is €61,670. In scenario 2, the ICERs of Simvastatin 20 mg and Rosuvastatin 10 mg are €199.933 and €61.238, respectively, while Rosuvastatin 10 mg dominates Simvastatin 20 mg. In both cases the Simvastatin 20 mg ICER is well above the €50.000 per life year gained threshold. However, Simvastatin 20 mg is the most prescribed alternative in Portugal. In fact, during 2006 its market share was around 66%, while Simvastatin 10 mg accounted just for 2% and Rosuvastatin 10 mg for 12%. Future research will show how results change with the market launch of Rosuvastatin 5 mg. CONCLUSION: Doctors are not influenced by economic evaluation when prescribing statins. Results show that Simvastatin 10 mg should be used as first line and Rosuvastatin 10 mg as second line strategies. Most probably, the high market share of Simvastatin 20 mg reflects the "first mover" advantage in the market.
PCV99 THE FIRST MOVER STRIKES AGAIN. COST-EFFECTIVENESS OF STATINS AND PRESCRIBING BEHAVIOR IN PORTUGAL
